Palobiofarma — Series C (estimated) · €4.5M

Palobiofarma closed its third round, €4.5M, from Sodena, Inveready Biotech II and Fitalent. The money funds early clinical work on four adenosine-receptor compounds (PBF-509, PBF-680, PBF-695 and PBF-999). As part of the deal the company moved its headquarters to Navarra and opened a lab at the CEIN incubator.